GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Heartware International Inc (NAS:HTWR) » Definitions » Interest and Commission Paid

Heartware International (Heartware International) Interest and Commission Paid


View and export this data going back to 2008. Start your Free Trial

What is Heartware International Interest and Commission Paid?

Interest and Commission Paid only applicable to companies reporting Cash Flow from Operations in direct method.

Heartware International (Heartware International) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Heartware International Inc (NAS:HTWR) » Definitions » Interest and Commission Paid
Comparable Companies
XTER:EUZ SHSE:688389 NTUS SWAV TSE:7575 XTER:DRW3 SHSE:688108 TSE:6960 HKSE:01858 SZSE:300298 SILK CRY VREX XTER:SBS CVRS SHSE:688139 TCMD XKRX:214150 SHSE:603387 OFIX
Traded in Other Exchanges
N/A
Address
Website
http://www.heartware.com
Heartware International Inc was incorporated in Delaware on July 29, 2008 and became the successor issuer to HeartWare Limited, an Australian corporation, on November 13, 2008, as a result of the Australian Court approved redomiciliation of HeartWare Limited from Australia to Delaware. HeartWare is a medical device company engaged in developing implantable blood pumps for the treatment of advanced heart failure. The Company operates one reportable segment which includes the design, manufacture and marketing of medical devices for the treatment of advanced heart failure. The HeartWare Ventricular Assist System, which includes a left ventricular assist device, or blood pump, patient accessories and surgical tools, is designed to provide circulatory support for patients with advanced heart failure. Beyond the HeartWare System, the company is also evaluating its next device, the Miniaturized Ventricular Assist Device. The MVAD is based on the same technology platform as the HeartWare System but adopts an axial flow, rather than a centrifugal flow, configuration and is being developed in multiple configurations. The MVAD designs are currently at the preclinical stage and undergoing animal studies focused on minimally invasive implantation techniques and are each approximately one-third the size of the HVAD Pump. The Company's competitors in the implantable cardiac assist space include Thoratec Corporation, Jarvik Heart, Inc., MicroMed Cardiovascular, Berlin Heart GmbH, and Sunshine Heart, Inc. HEARTWARE, HVAD, MVAD, PAL, CIRCULITE, SYNERGY and various company logos are the trademarks of the Company, in the United States, Europe, Australia and other countries.
Executives
Larkin C Raymond Jr director C/O MALLINCKRODT INC, 7733 FORSYTH BLVD, ST LOUIS MO 63105
Stephen N. Oesterle director ONE BAXTER PARKWAY, DEERFIELD IL 60015
Cynthia L Feldmann director 17 WINTHROP ROAD, WAYLAND MA 01778
Seth Loring Harrison director 230 PARK AVENUE, SUITE 2800, NEW YORK NY 10169
Timothy J Barberich director 40 ELM ST, CONCORD MA 01752
Douglas Evan Godshall director, officer: President & Chief Exec Officer SUITE 4 LEVEL 46 2 PARK STREET, SIDNEY C3 2000
Robert Bain Thomas director SUITE 4 LEVEL 46 2 PARK STREET, SIDNEY C3 2000
Denis Newell Wade director SUITE 4 LEVEL 46, 2 PARK STREET, SIDNEY C3 2000
Adage Capital Partners Gp, L.l.c. 10 percent owner 200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Adage Capital Partners, L.p. 10 percent owner 200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Adage Capital Advisors, L.l.c. 10 percent owner 200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Robert Atchinson 10 percent owner 200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Phillip Gross 10 percent owner 200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
David Mcintyre officer: CFO & COO SUITE 4 LEVEL 46 2 PARK STREET, SIDNEY C3 2000
Muneer A Satter 10 percent owner C/O SATTER INVESTMENT MANAGEMENT, LLC, 676 NORTH MICHIGAN AVENUE, SUITE 4000, CHICAGO IL 60611